Molnupiravir was given to people twice a day, for five days at home, while they had the Omicron variant of Covid.
Those chosen were at a higher risk of death or hospitalisation from Covid due to age or underlying health conditions.
Despite aiding recovery, the drug did not decrease death rates or hospital admissions. BBC News
See also:
- Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial (open access) The Lancet
- Two years after Covid food still tastes rotten BBC News
- Covid drug DOESN'T cut risk of dying but it might help you recover quicker at home The Daily Mail
- Antiviral does not cut Covid hospital admissions or deaths in vaccinated – study The Independent
No comments:
Post a Comment